Ichnos Sciences Welcomes Eric Feldman, M.D., as New Chief Medical Officer
Retrieved on:
Monday, November 8, 2021
ADC, Cancer, Lymphatic system, Leukemia, Industry, Regulatory science, CMO, Clinical and Translational Science, R, Health, Organization, Knowledge, Myeloid leukemia, CEO, Professor, Hospital, Acute myeloid leukemia, Tulane University, Leukemia Research (journal), Senior, Research, New York Medical College, Biometrics, Glycomimetic, Therapy, Degenerative disease, BEAT, Patient, Drug, Seagen, Pharmacokinetics, Pharmaceutical industry
NEW YORK, Nov. 8, 2021 /PRNewswire/ --Ichnos Sciences Inc., a global biotechnology company developing innovative biologic treatments in oncology and autoimmune diseases, today announced the appointment of Eric J. Feldman, M.D., to the position of Chief Medical Officer (CMO), effective immediately.
Key Points:
- NEW YORK, Nov. 8, 2021 /PRNewswire/ --Ichnos Sciences Inc., a global biotechnology company developing innovative biologic treatments in oncology and autoimmune diseases, today announced the appointment of Eric J. Feldman, M.D., to the position of Chief Medical Officer (CMO), effective immediately.
- Dr. Feldman, who reports to President and Chief Executive Officer Cyril Konto, M.D., will be responsible for all pipeline development activities, including Clinical Development, Clinical Operations, Regulatory Sciences, Pharmacokinetics and Translational Sciences, Biometrics and Drug Safety.
- Previously, Dr. Feldman served as Senior Vice President, Chief Medical Officer, at GlycoMimetics, leading the Phase 3 registration study of uproleselan in acute myeloid leukemia, as well as other early-stage assets.
- Dr. Feldman received a medical degree at New York Medical College, and he holds a B.A.